Rain Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Rain Oncology

04/05/2022 23:35

* Rain Therapeutics Inc  RAIN.OQ  reported a quarterly
adjusted
loss of 66 cents​​ per share for the quarter ended in March. The
mean expectation of five analysts for the quarter was for a loss
of 70 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Rain Therapeutics Inc's reported EPS for the quarter was a
loss
of 66 cents​.
    * The mean earnings estimate of analysts had fallen by
about 32.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Rain Therapeutics Inc shares had fallen by 26.2% this
quarter and lost 71.0% so far this year.
    * The company reported a quarterly loss of $17.39 million.
    * Wall Street's median 12-month price target for Rain
Therapeutics
Inc is $20.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 4 at 10:35 p.m.  ​All
figures in US dollars unless otherwise stated